Bai Ze Medical (02609.HK): Reasons for Being a Popular Hong Kong Stock and Risk Analysis

Bai Ze Medical (02609.HK) is a Hong Kong stock in the medical sector. As of 09:58 on December 11, 2025 (UTC+8), its share price was HK$4.30 [1]. The stock has attracted widespread market attention due to a cumulative drop of 25.9% over 9 consecutive trading days, hitting a new post-listing low [1]. Additionally, Green Economy (01315.HK) announced on December 9, 2025 that it had illegally sold all its holdings of Bai Ze Medical shares in September, which constituted a major transaction but was not reported in accordance with Hong Kong Stock Exchange rules [2]. The latest ESG rating from Huazheng Index shows that Bai Ze Medical is only rated CCC (the lowest grade in this rating system is C) [3].
Price and成交量方面，该股11月21日报5.75港元[4]，至事件发生时累计跌幅达25.2%；当日成交量为92.4万股，成交金额404.75万港元，RSI14（相对强弱指标）为17.714，处于超卖区间[1]。资金流向显示主动买沽比率为24:76，净主动卖出204.65万港元，市场卖出情绪浓厚[1]。

1. Significant Decline Exceeding Sector Average
   : Although the Hong Kong medical sector has shown mixed performance overall, Bai Ze Medical’s consecutive decline is far greater than other stocks in the sector, possibly due to the combined impact of its related illegal incident and low ESG rating [1].
2. Oversold Status and Persistent Selling Pressure
   : The 14-day RSI (Relative Strength Index) is in the oversold range, so there may be potential for a technical rebound in the short term. However, the 76% share of active sell orders indicates weak investor confidence, which may limit the rebound momentum [1].
3. Illegal Incident May Attract Regulatory Attention
   : Green Economy’s illegal share sale was not disclosed in accordance with rules, which may lead the Stock Exchange of Hong Kong to launch a regulatory review of Bai Ze Medical, further affecting the company’s market reputation [2].

• Sustained Downward Pressure
  : Without obvious positive support, the downward trend over 9 consecutive trading days may continue [1].
• Regulatory and Reputational Risks
  : The illegal incident may trigger regulatory actions, reducing investors’ trust in the company [2].
• Reduced Institutional Holding Willingness
  : The low ESG rating may lead institutional investors to reduce or avoid holdings [3].

• Oversold Rebound Opportunity
  : The 14-day RSI is in the oversold range, so there may be a rebound in the short term due to technical adjustments. However, it is necessary to closely monitor whether the support level of HK$4.30 is broken [1].

Bai Ze Medical (02609.HK) is currently facing multiple pressures including consecutive declines, related illegal incidents, and a low ESG rating. As of December 11, 2025, its share price is HK$4.30, with a 9-day cumulative drop of 25.9% and a trading volume of 924,000 shares. Active sell orders account for 76%, indicating weak market sentiment. It is necessary to continue monitoring the stability of the HK$4.30 support level and subsequent regulatory developments.